Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

nced the reduction in tumor volume produced by cyclophosphamide and cisplatin. There was a 130 percent, 65 percent and 70 percent decrease in the tumor volume of animals administered with SPI (IRL)-1620 plus cyclophosphamide as compared to cyclophosphamide alone on day 10, 16 and 22, respectively. Similarly, the reduction in tumor volume in SPI (IRL)-1620 plus cisplatin treated animals was 31 percent, 68 percent and 80 percent greater on day 10, 16 and 22, respectively compared to cisplatin alone treated animals.

Conclusion

In conclusion, SPI (IRL)-1620 significantly enhanced the efficacy of cyclophosphamide and cisplatin in a preclinical model of ovarian tumor in mice.

About EOquin

EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the inner most lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study for which patient accrual was completed this year, EOquin instilled into the bladder following TUR-BT was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, would carry a low risk of harming the rest of the body.

Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced 67% CRs (complete responses) in patients, many of whom had been treated multiple times. EOquin received a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for non-invasive bladder cancer and the Company expects to begin enrollment of the first patients in the Phase 3 trial this quarter.

About Satraplatin

Satraplatin, a fourth-generation, oral investigational drug, is a member of the plati
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:10/25/2014)... October 24, 2014 Research ... addition of the "Global and Chinese Hemodialysis ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ...
(Date:10/25/2014)... , Oct. 24, 2014  In 2008, two of ... quantities of multiple controlled substances, on a regular basis, ... reported that Dr. Gurney was practicing "all the time" ... one of his employees said that Dr. Gurney was ... of patients." Dr. Gurney,s behavior became increasingly ...
(Date:10/25/2014)... 24, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Monday, November 3, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... GLEN ALLEN, Va., Feb. 9, 2011 Rock Creek ... CIGX ) announced that on February 4 a ... Trademark Office ("PTO") for administering a pure form of ... be administered in a composition containing a therapeutically effective ...
... 2011 Cyberonics, Inc. (Nasdaq: CYBX ) today ... third quarter ended January 28, 2011 of its fiscal year ... regular market trading hours.  The company will conduct a conference ... 7:30 AM Central Time (8:30 AM Eastern Time). ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 3Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 4Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011 2
(Date:10/25/2014)... Limbkeepers® announced today that they will ... Ed Begley Jr, airing 1st QTR 2015 via Discovery ... episode, Innovations will focus on Limbkeepers® non compression knit ... skin on arms, hands, and legs from abrasion, skin ... products, which help reduce injuries, allow for continued daily ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
Breaking Medicine News(10 mins):Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... CLEMENS, Mich., Nov. 25 Two more H1N1 vaccine clinics have ... Macomb County Health Department announced today. They are being offered at ... in Sterling Heights. , The Dec. 3 clinic will be held ... from 9 a.m. to 3 p.m. The thimerosol-free version of the ...
... Fla., Nov. 25 Daniel Touizer, CEO of Ci n ... guaranteed issue health insurance benefit programs, is concerned that the labor department,s recently ... job and unlikely to have health insurance. , "True unemployment ... highest rate in over 20 years," says Dani e ...
... and Spanish . Researchers from the ... ocular diseases that are very common today, such as age-related macular ... had never before been used for this purpose. Scientists from ... affected by one of these two pathologies, finding a greater amount ...
... available in French . Montreal, November 25, ... marketplace, thanks to a new partnership between Gestion Univalor, ... privately owned technology company based in Montreal. Univalor, ... its affiliated institutions, and CSI have announced the signature ...
... Discovery in fruit fly study may lead to new drugs ... -- Sphingadienes, natural lipid molecules found in soy, could become ... have found. , The findings are preliminary, but the ... soy seems to provide protection against colon cancer. , In ...
... experts offer waistline-friendly ways to enjoy festive feasting , WEDNESDAY, ... holiday smorgasbord from Thanksgiving to New Year,s, but are already ... come Jan. 1, help is at hand. , It,s possible, ... make it to 2010 weighing the same as you do ...
Cached Medicine News:Health News:Macomb County Health Department Schedules Two More H1N1 Flu Vaccine Clinics Dec. 3 and 5 2Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: